Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 5, 2005 - Issue 5
Submit an article Journal homepage
37
Views
4
CrossRef citations to date
0
Altmetric
Perspective

Challenges and opportunities: what we are learning from the clinical natalizumab experience

Norman J Kachuck USC Keck School of Medicine, 1520 San Pablo Street, 3000 Los Angeles CA 90033, USA. [email protected]
Pages 605-615 | Published online: 10 Jan 2014

References

  • Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169–178 (2002).
  • Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. 353, 362–368 (2005).
  • Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375–381 (2005).
  • Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β1a for multiple sclerosis. N. Engl. J. Med. 353, 369–374 (2005).
  • Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab – unforeseen consequences. N. Engl. J. Med. 353, 414–416 (2005).
  • Compston A, Coles A. Multiple sclerosis. Lancet 359, 1221–1231 (2002).
  • Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125, 2202–2212 (2002).
  • Geurts JJ, Bo L, Pouwels PJ et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Am. J. Neuroradiol. 26, 572–577 (2005).
  • Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 23, 1168–1175 (2004).
  • Martino G. How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders. Lancet Neurol. 3(6), 372–378 (2004).
  • Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 1–5 (2005).
  • Lassmann H, Ransohoff RM. The CD4–Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol. 25, 132–137 (2004).
  • Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47(6), 707–177 (2000).
  • Rice GPA, Hartung HP, Calabresi PA. Anti{α}4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64, 1336–1342 (2005).
  • Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Rev. Drug Discov. 4, 510–518 (2005).
  • Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurother. 4, 571–580 (2004).
  • Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting α4 integrin. Am. J. Gastroenterol. 98(11), 2372–2382 (2003).
  • Carrithers MD, Visintin I, Kang SJ, Janeway CA Jr. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 123, 1092–1101 (2000).
  • Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15–23 (2003).
  • Miller DH, O’Connor P, Havrdova E et al. For the AFFIRM investigators. American Academy of Neurology National Meeting, FL, USA (2005).
  • O’Connor P, Havrdova E, Hutchinson M et al. For the AFFIRM Investigators. American Academy of Neurology Annual Meeting, FL, USA (2005).
  • Rudick R, Stuart W, Calabresi PA et al. For the SENTINEL Investigators. American Academy of NeurologyAnnual Meeting, FL, USA (2005).
  • Goodman A. Platform presentation at the American Academy of Neurology Annual Meeting, FL, USA (2005).
  • Phillips JT, O’Connor P, Havrdova E et al. Platform presentation at the American Academy of Neurology Annual Meeting, FL, USA (2005).
  • Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann. Neurol. 49, 677–681 (2001).
  • Ellenberg SS. Scientific and ethical issues in the use of placebo and active controls in clinical trials. J. Bone Miner. Res. 18, 1121 (2003).
  • Emanuel EJ, Miller FG. The ethics of placebo-controlled trials – a middle ground. N. Engl. J. Med. 345, 915–918 (2001).
  • Emanuel EJ, Wood A, Fleischman A et al. Oversight of human participants research: identifying problems to evaluate reform proposals. Ann. Intern. Med. 141, 282–291 (2004).
  • Horig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nature Med. 11, 705 (2005).
  • Koski G, Nightingale SL. Research involving human subjects in developing countries. N. Engl. J. Med. 342 (2001).
  • Lewis JA, Kreutz G, Sampaio C, van Zwieten-Boot B. Placebo-controlled trials and the Declaration of Helsinki. Lancet 359, 1337–40 (2002).
  • Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann. Neurol. 49(5), 677–681 (2001).
  • Paller MS, Hostetler L, Dykhuis DA. Clinical trials at AHCs: The perspective of an academic clinical trials office. Acad. Med. 77, 1201–1206 (2000).
  • Reynolds T. The ethics of placebo-controlled trials. Ann. Intern. Med. 133, 491–492 (2000).
  • Shapiro HT, Meslin EM. Ethical issues in the design and conduct of clinical trials in developing countries. N. Engl. J. Med. 345 (2001).
  • Weijer C. The ethics of placebo-controlled trials. J. Bone Miner. Res. 18, 1150–1153 (2003).
  • Noseworthy JH, O’Brien P, Erickson BJ et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51, 1342–1352 (1998).
  • Angell M. The Truth about the Drug Companies. Random House, NY, USA (2004).
  • Theien BE, Vanderlugt CL, Eagar TN et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107, 995–1006 (2001).
  • Theien BE, Vanderlugt CL, Nickerson-Nutter C et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 102, 4464–4471 (2003).
  • Garcia De Viedma D, Diaz Infantes M, Miralles P et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin. Infect. Dis. 34, 1568–1575 (2002).
  • Henmi C, Sawa H, Iwata H Orba Y, Tanaka S, Nagashima K. Establishment of an immunoscreening system using recombinant VP1 protein for the isolation of a monoclonal antibody that blocks JC virus infection. Biochem. Biophys. Res. Commun. 327, 242–251 (2005).
  • Caruso M, Belloni L, Sthandier O, Amati P, Garcia MI. α4β1 integrin acts as a cell receptor for murine polyomavirus at the postattachment level. J. Virol. 77, 3913–3921 (2003).
  • Sawa H, Komagome R. The JC virus-like particle overlay assay. Methods Mol. Biol. 292, 175-86 (2005).
  • Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17, 376–370 (2004).
  • Blumberg BM, Mock DJ, Powers JM et al. The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J. Clin. Virol. 16, 159–178 (2000).
  • Goodman AD, Mock DJ, Powers JM, Baker JV, Blumberg BM. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J. Infect. Dis. 187, 1365–1376 (2003).
  • Lund BT, Ashikian N, Ta HQ et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J. Neuroimmunol. 155, 161–171 (2004).
  • Rollison DE, Utaipat U, Ryschkewitsch C et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int. J. Cancer 113, 769–774 (2005).
  • Whitea, Reissa K, Del Vallea L et al. Human polyomaviruses and brain tumors. Brain Res. Rev. (2005) (In Press).

Websites

  • Center for Drug Evaluation and Research, FDA. Questions and answers on natalizumab (marketed as Tysabri) www.fda.gov/cder/drug/infopage/natalizumab/natalizumabQA_2_2005.htm (Accessed August 2005)
  • Nih. Hyperaccelerated award/mechanisms in immunomodulation trials: rfa number: rfa-ai-04–001. http://grants1.nih.gov/grants/guide/rfa-files/RFA-AI-04-001.html (Accessed August 2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.